Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

Asian patients with non-cystic fibrosis bronchiectasis had a lower annualized exacerbation rate and less lung function ...

Dr. Drucy Borowitz helped turn cystic fibrosis from a deadly childhood illness into a treatable condition, giving families ...

Arcturus Therapeutics (($ARCT)) announced an update on their ongoing clinical study. Study Overview: Arcturus Therapeutics is conducting a Phase 2 ...

Generic Tobramycin Inhalation Solution marks the first cystic fibrosis (CF) product in the Company’s portfolio-Antibiotic is primarily used for ...

Commonwealth Bank has announced that 180 community organisations across Australia will share in $4.2 million through its 2025 ...

This study update could positively impact Vertex Pharmaceuticals and Moderna’s stock performance, as successful results may enhance their competitive position in the cystic fibrosis treatment market.

Saskatchewan’s Prescription Drug Plan is celebrating its 50th anniversary, marking five decades of helping residents access ...

Insmed INSM reported a third-quarter 2025 loss of $1.75 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.32. In the year-ago quarter, the company posted a loss of $1.27 per ...

Intervention/Treatment: The intervention being tested is a biological treatment known as BX004, a nebulized bacteriophage. This treatment is designed to target and reduce chronic Pseudomonas ...

Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...

The rise of infections caused by Mgen, C. auris, treatment-resistant E. coli, and more could become future public-health threats, experts say.